PPMC Penn Cardiology Clinical Case Management Conference Series 2024-

PPMC Penn Cardiology Clinical Case Management Conference Series 2024-2025 - 6/4/2025 June 4, 2025 7:30 AM - 8:30 AM Online or Penn Presbyterian Medical Center

Target Audience

This program has been designed for INTERNAL MEDICINE - Clinical Cardiac Electrophysiology, INTERNAL MEDICINE - Advanced Heart Failure and Transplant Cardiology, INTERNAL MEDICINE - Interventional Cardiology

Series Educational Objectives

After participating in this regularly scheduled series, participants should be able to:

- 1 Improve communication between team members.
- 1 Describe how to access existing resources to improve patient care
- 2 Discuss current or upcoming clinical studies that may benefit patients.

Accreditation

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physicians: Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)* $^{\text{TM}}$. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: This activity is for 1.00 contact hours.

Pharmacists: This activity is not approved for pharmacy contact hours

PAs: AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit*[™] from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of **1.00** Category 1 credits for completing this activity.

Approved for (PSRM) patient safety/risk management designation

Acknowledgement of Commercial Support*

None

For more information, please contact Natalie Bleu, Kyera Jackson (215) 662-9746, (215) 662-8525

Natalie.bleu@pennmedicine.upenn.edu, kyeraj@upenn.edu



Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships(RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based, are based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant, and applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

| Name of individual | Individual's role in activity | Nature of Relationship(s) / Name of Ineligible Company(s) |
|---------------------------|------------------------------------|---|
| Stephen M Chrzanowski, MD | Other Planning Committee Member | Nothing to disclose - 04/18/2025 |
| Ross R Zimmer , MD | Other Planning Committee Member | Nothing to disclose - 11/24/2024 |
| Robert Li, MD | Other Planning Committee Member | Nothing to disclose - 10/17/2024 |
| Norman Feinsmith, MD | Other Planning Committee Member | Consulting Fee-Johnson & Johnson - 04/18/2025 |
| Fern M Kaufman, CRNP RN | Other Planning Committee Member | Nothing to disclose - 10/17/2024 |
| Harvey L Waxman, MD | Other Planning Committee Member | Nothing to disclose - 02/27/2025 |
| Gary J. Vigilante, MD | Other Planning Committee Member | Nothing to disclose - 02/27/2025 |
| Alan Askenase, MD-FCBC | Other Planning Committee Member | Nothing to disclose - 02/27/2025 |
| Jignesh Bhavsar, MD | Other Planning Committee Member | Nothing to disclose - 12/03/2024 |
| Wilson Y Szeto, MD | Other Planning Committee Member | Grant or research support-Edwards Lifesciences Grant or research support- Terumo Grant or research support- Medtronic Consulting Fee- Artivion Consulting Fee-Microinterventional device Consulting Fee-Medeon - 01/08/2025 |
| Sameer Khandhar, MD | Other Planning Committee | Nothing to disclose - 11/06/2024 |

| | Member | |
|----------------------|------------------------------------|--|
| Joshua Liez, MD | Other Planning Committee Member | Nothing to disclose - 02/27/2025 |
| Neil Levin, MD | Other Planning Committee Member | Nothing to disclose - 05/01/2025 |
| Carl R Reynolds, MD | Course Director, Faculty | Nothing to disclose - 02/25/2025 |
| Michael Ibrahim, MD | Other Planning Committee Member | Nothing to disclose - 02/25/2025 |
| John Bullinga, MD | Other Planning Committee Member | Consulting Fee-Medtronic (Relationship has ended) - 03/17/2025 |
| Benjamin D'Souza, MD | Other Planning Committee Member | Nothing to disclose - 05/27/2025 |
| Rupal P. O'quinn, MD | Other Planning Committee Member | Consulting Fee-Astra Zeneca Pharmaceuticals (Relationship has ended) Honoraria-Belgium Hematology Society (Relationship has ended) Honoraria-Virtua - Grand Rounds (Relationship has ended) Consulting Fee-Bracco - core reader for research echos Honoraria-Zoll Services LLC (Relationship has ended) - 04/15/2025 |
| Roy Arjoon, MD | Other Planning Committee Member | Nothing to disclose - 04/21/2025 |
| Chase Brown, MD | Other Planning Committee Member | Nothing to disclose - 12/13/2024 |
| Robert Fenning, MD | Other Planning Committee Member | Stocks or stock options, excluding diversified mutual funds of a publicly traded company-Medtronic Stocks or stock options, excluding diversified mutual funds of a publicly traded company-Novartis (Advanced Health Media) Stocks or stock options, excluding diversified mutual funds of a publicly traded company-Eli Lilly and Company Stocks or stock options, excluding diversified mutual funds of a publicly traded company-Penumbra Stocks or stock options, excluding diversified mutual funds of a publicly traded company-Inari Medical Stocks or stock options, excluding diversified mutual funds of a publicly traded company-Edwards Lifesciences Stocks or stock options, excluding diversified mutual funds of a publicly traded company-Pfizer, Inc 12/12/2024 |
| Todd Mendelson, MD | Other Planning Committee Member | Nothing to disclose - 07/02/2024 |
| Ellen Malone, CRNP | Nurse Planner | Nothing to disclose - 08/23/2024 |
| Gene Chang, MD | Other Planning Committee Member | Grant or research support-Abbott/St. Jude Grant or research support-Edwards Lifesciences Grant or research support- Cardiac Dimensions - 03/27/2025 |

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding

diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected